| Methods |
STUDY DESIGN: Parallel group, single centre Germany, 12 weeks
RANDOMISATION: Yes, no method stated.
BLINDING: not stated and no details in paper
WITHDRAWALS/DROP OUTS: All completed, no withdrawals.
COMPLIANCE: Not assessed
CONFOUNDERS: Groups well balanced by characteristics
QUALITY: Jadad 2. Cochrane B |
| Participants |
N = 22 RANDOMISED/COMPLETED, children, M = 15 F = 7 Mean age: 9.7 (SD 3.5)
BASELINE SEVERITY: Mild asthma, not requiring additional therapy other than SABA
INCLUSION : Mild asthma, requiring no preventive therapy.
EXCLUSION: Requiring additional therapy for asthma. |
| Interventions |
LONG ACTING BETA AGONIST: Formoterol 24 mcg BD
SHORT ACTING BETA AGONIST: Salbutamol 200 mcg QDS
PLACEBO: none
DEVICE: not specified
TREATMENT PERIOD: 12 weeks
RESCUE: none required
CO‐INTERVENTIONS: none |
| Outcomes |
OUTCOMES: FEV1, FVC, histamine provocation, beta‐receptor binding sites on mononuclear leucocytes, adverse events |
| Notes |
Histamine provocation only until subjective endpoint, not 20% fall in FEV1. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
Information not available (Cochrane Grade B) |
